Alendronate indications

List of indications
Treatment of Osteoporosis Prevention of Osteoporosis Increase Bone Mass in Men Glucocorticoid-Induced Osteoporosis Paget's Disease Postmenopausal Women

Treatment of Osteoporosis
For the treatment of osteoporosis, FOSAMAX increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. Return to top

Prevention of Osteoporosis
For the prevention of osteoporosis, FOSAMAX may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of FOSAMAX for prevention of osteoporosis. Return to top

Increase Bone Mass in Men
Treatment to increase bone mass in men with osteoporosis. Return to top

Glucocorticoid-Induced Osteoporosis
Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Return to top

Paget's Disease
Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. Return to top

Postmenopausal Women
Treatment and prevention of osteoporosis in postmenopausal women. Return to top